Belgium-based Agomab will use some of the proceeds to fund a recently-started phase 2 trial of its lead ALK5 inhibitor AGMB-129 for fibrostenosing Crohn’s disease, a severe form that often ...

And Agomab's novel ALK5 inhibitor (AGMB-129) met its primary endpoint in a phase II trial of fibrostenosing Crohn's disease, the company announced. Tapering prednisolone reduced the risk of ...